PALISADE BIO INC
PALINASDAQTrading Snapshot
- Day Range
- $1.43 – $1.46
- 52-Week Range
- $0.83 – $2.86
- Volume
- $3.78B
- Avg Volume
- $4.81B
- Shares Outstanding
- 173.6M
- Next Earnings
- Dec 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $500,000
- Last Q Revenue
- $500,000
- P/E Ratio
- -2.7
- P/S Ratio
- 503.4x
- EPS (TTM)
- $-0.15
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +551.9%
Why Investors Own PALI
- ✓High-growth profile — revenue up -3.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PALISADE BIO INC
PALI
StockOtter · stockotter.spaceAbout PALISADE BIO INC
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026
Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn's disease
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
Palisade Bio (NASDAQ: PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease after completing its Phase I program. Chief Executive Officer JD Finle
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
Palisade Bio NASDAQ: PALI said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease after completing its Phase I program.
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis e
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD
ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn's disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 Phas
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biophar